$70,000.00 in Sales Expected for Vical Incorporated (VICL) This Quarter
Equities research analysts expect that Vical Incorporated (NASDAQ:VICL) will announce sales of $70,000.00 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Vical’s earnings, with estimates ranging from $30,000.00 to $100,000.00. Vical reported sales of $720,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 90.3%. The firm is expected to report its next quarterly earnings results on Thursday, May 2nd.
On average, analysts expect that Vical will report full year sales of $260,000.00 for the current fiscal year, with estimates ranging from $120,000.00 to $400,000.00. For the next fiscal year, analysts anticipate that the business will post sales of $0.00. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Vical.
Vical (NASDAQ:VICL) last released its quarterly earnings results on Tuesday, February 19th. The biotechnology company reported ($0.17) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.17). The business had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.04 million. Vical had a negative return on equity of 33.58% and a negative net margin of 1,002.10%.
NASDAQ:VICL remained flat at $$1.22 during mid-day trading on Friday. The company had a trading volume of 1,407 shares, compared to its average volume of 309,439. The firm has a market cap of $26.18 million, a PE ratio of -1.51 and a beta of 0.53. Vical has a 1-year low of $0.85 and a 1-year high of $1.82.
In other Vical news, major shareholder Armistice Capital Master Fund sold 2,190,500 shares of Vical stock in a transaction on Thursday, January 10th. The stock was sold at an average price of $0.88, for a total value of $1,927,640.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.58% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in Vical by 47.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 138,960 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 44,723 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Vical by 10.1% in the 3rd quarter. Renaissance Technologies LLC now owns 966,549 shares of the biotechnology company’s stock valued at $1,324,000 after acquiring an additional 88,820 shares in the last quarter. Finally, Sio Capital Management LLC acquired a new position in Vical in the 3rd quarter valued at $1,699,000. 46.64% of the stock is owned by hedge funds and other institutional investors.
Vical Company Profile
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection.
Recommended Story: Average Daily Trade Volume – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.